The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

In a report released on January 24, Anthony Elian from J.P. Morgan maintained a Sell rating on Texas Capital Bancshares (TCBI – Research ...

Two Senate committees are expected to question Robert F. Kennedy Jr. on how his disproven views of science and medicine ...

Some health professionals have spoken out about President Donald Trump’s nomination of Robert F. Kennedy, Jr., for Secretary ...

When Cate Luzio founded networking and educational platform Luminary in 2018, she aimed to make an inclusive environment that ...

Erin Whaley, Tammy Ward Woffenden and Paul M. Mahoney Jr. of Troutman Pepper Locke LLP discuss key market and legal developments impacting health care delivery that will be top of mind for investors ...

Purchase of Intra-Cellular will give J&J control of mental health drug Caplyta, which CEO predicts will become a $5 billion ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

In a report released yesterday, Samik Chatterjee from J.P. Morgan maintained a Buy rating on Corning (GLW – Research Report), with a price ...

Trump’s pick to lead HHS is facing 175 questions from Elizabeth Warren, skepticism from Mike Pence and delays related to his ...